• Mar Riveiro-Barciela, Ernesto Trallero-Araguás, Fernando Martínez-Valle, Vall d’Hebrón Group for the study of Immunotherapy immune-related adverse events, and Vall d’Hebrón Committee for management of Immunotherapy immune-related adverse events.
• Liver Unit, Internal Medicine Department, Hospital Universitari Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.
• Med Clin (Barc). 2020 Dec 24; 155 (12): 541-547.

AbstractIn recent years, immunotherapy has become an important pillar of cancer treatment, with high response rates regardless of tumour histology or baseline mutations. However, immune activation associated with check-point inhibitors is not selective and a large variety of immune-related adverse events have been associated with anti-PD1, anti-PD-1/L-1 and anti-CTLA-4 agents. Though diagnosis and treatment of these toxicities have been established according to the recommendations from clinical trials and in line with the autoimmune disorders that they mimic, increasing real-world data is coming up showing that these adverse events may have differential characteristics and management, especially in terms of the use of corticoids, second-line treatments, salvage therapy for life-threatening cases and reintroduction of immunotherapy. Herein we present a comprehensive review of current recommendations and real-world data on the main immune-related adverse events of immunotherapy.Copyright © 2020 Elsevier España, S.L.U. All rights reserved.

9 keywords...

hide…